The ASGE gave the ORBERA system a nod for meeting its Preservation and Incorporation of Valuable Endoscopic Innovations threshold standards for the treatment of obesity.
“ORBERA’s recognition by ASGE as the only endoscopic treatment that currently meets their predetermined efficacy threshold underscores the importance of ORBERA as a proven and effective non-surgical solution to help patients and their doctors fight obesity before their disease requires more invasive treatments,” said Todd Newton, CEO of Apollo Endosurgery.
More articles on gastroenterology:
FDA approves new CRC drug
15 things to know about gastroenterology for ASCs
Beyond patient care: The biggest challenges in GI
